Palatin Technologies Inc. has released its financial results for the fiscal third quarter ended March 31, 2025. The company reported no product sales for the quarter, following the completion of the sale of Vyleesi's worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals in December 2023, for up to $171 million. The net loss for the quarter was $4.8 million, showing a significant improvement from the $8.4 million loss for the same period in 2024. This decrease in net loss was primarily driven by a reduction in operating expenses, which fell to $4.8 million from $9.2 million in the previous year, mainly due to decreased spending related to Palatin's MCR programs. Palatin's cash and cash equivalents stood at $2.5 million as of March 31, 2025, down from $9.5 million as of June 30, 2024. However, this figure does not include approximately $3.5 million of net proceeds received in April and May 2025 from the company's ATM facility and equity offering. Palatin is actively engaging with potential funding sources for future operating cash requirements. In other financial metrics, the net cash used in operations for the quarter was reduced to $5.4 million from $8.6 million in the same quarter of the previous year. Total other income/expense, net, for the quarter ended March 31, 2024, included a fair value adjustment gain of $0.4 million.